on STAT3 druggability
Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides (ASOs)
https://mct.aacrjournals.org/content/early/2021/01/21/1535-7163.MCT-20-0599
Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides (ASOs)
https://mct.aacrjournals.org/content/early/2021/01/21/1535-7163.MCT-20-0599
$AZN $IONS danvatirsen data at ESMO in 2017 w/ durva in HNSCC
https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2820%2938403-9
update at ESMO 2018 w/ durva in HNSCC
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/A-phase-1b-2-study-SCORES-of-durvalumab-D-plus-danvatirsen-DAN-AZD9150-or-AZD5069-CX2i-in-advanced-solid-malignancies-and-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-RM-HNSCC-Updated-results
ph1 publi in R/R DLBCL in 2020, also w/ durva
https://www.sciencedirect.com/science/article/pii/S2152265020310181
investigated by $AZN in NSCLC, TNBC, NHL
https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2820%2938403-9
update at ESMO 2018 w/ durva in HNSCC
https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/A-phase-1b-2-study-SCORES-of-durvalumab-D-plus-danvatirsen-DAN-AZD9150-or-AZD5069-CX2i-in-advanced-solid-malignancies-and-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma-RM-HNSCC-Updated-results
ph1 publi in R/R DLBCL in 2020, also w/ durva
https://www.sciencedirect.com/science/article/pii/S2152265020310181
investigated by $AZN in NSCLC, TNBC, NHL